Update: Pipeline expansion
Regeneus has added another project to its portfolio, with licensing of global rights to an autologous human cancer vaccine that is expected to enter the clinic in Q115. Developed at the Kolling Institute, Sydney, the technology was already licensed to Regeneus for veterinary applications (Kvax), which is now in a US marketing trial for osteosarcoma in dogs. Cancer immunotherapy, including multiple approaches to cancer vaccines, is a biotech hotspot and we look forward to progress with Regeneus’s new candidate. Our overall valuation is now A$145m, or A$0.79 per share.Regeneus is engaged in the development and commercialization of proprietary adipose-derived stem cell technologies used by physicians and veterinarians to treat musculoskeletal conditions in humans and animals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.